# 510(k) Summary

In accordance with the requirements of 21 CFR.807.92, the following information about $5 1 0 ( \mathbf k )$ safety and effectiveness is being submitted.

# 1. Submitter

CERAGEM Medisys Inc.   
16 Jeongjil-gil. Seonggeo-eup. Seobuk-gu, Cheonan-si. Chungcheongnam-do. 331-833, Korea Phone : $( + 8 2 )$ 41-529-8422   
Fax : $( + 8 2 )$ 41-551-0767

Date Prepared

February 28. 2014

Device Name

Common name : CERA-CHEK 1070 Blood Glucose Monitoring System   
Classification : Class II (Regulation: 21 CFR § 862.1345)   
Product Code $:$ LFR. NBW(Blood Glucose Test System, Over the Counter), JJX, JQP

Predicate Device

CERA-CHEK 1070 Blood Glucose Monitoring System is substantially equivalent to Ascensia® CONTOUR $^ \mathrm { \textregistered }$ Blood Glucose Monitoring System described as below.

Device Nam:AscensiCONTOUR  Blood Glucose Monioring System Manufacturer: Bayer HealthCare, LLC.   
(510(K) Number: K062058

Device Description

The CERA-CHEK 1070 Blood Glucose Monitoring System consists of the CERA-CHEK 1070 Glucose Test Meter. CERA-CHEK 1070 Blood Glucose Test Strips with Code Key. CERA-CHEK I070 Control Solution I and Control Solution 2, a Lancing device, and CERACHEK Diabetes Management Software and cable needed for installing the software on the PC and for transmitting data from meter. Control Solution 1 and Control Solution 2 are required but not included with the meter. Control Solution 1 and Control Solution 2 are always

provided as a set. CERA-CHEK Diabetes Management Software and cable are required but not included with the meter. CERA-CHEK Diabetes Management Software and cable are always provided as a set.

# Intended Use

The CERA-CHEK 1070 Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip, forearm, upper arm, palm. thigh, or calf. The CERA-CHEK 1070 Blood Glucose Monitoring System is intended to be used by a single person and should not be shared. Alternative site testing should be done only during steady-state times (when glucose is not changing rapidly).

The CERA-CHEK 1070 Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic usc) by people with diabetes at home as an aid to monitor the effectiveness of diabetes controls. The CERA-CHEK 1070 Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use.

The CERA-CHEK 1070 Blood Glucose Test Strips are for use with the CERA-CHEK 1070 Blood Glucose Test Meter to quantitatively measure glucose (sugar) in fresh capillary whole b sp dra rom thefngert frear, uper ar, pal, thil.

The CERA-CHEK 1070 Control Solution is for usc with the CERA-CHEK 1070 Blood Glucose Test Meter and Test strips as a quality control check to verify that the meter and test ss rk  on hae y.

The CERA-CHEK Diabetes Management Software is PC-based software intended for use in home and professional settings to help people with diabetes and their healthcare professionals in the review. analysis and evaluation of glucose results for effective diabetes management. It is intended for use as an accessory to compatible CERAGEM MEDISYS blood glucose monitoring systems. The CERA-CHEK Diabetes Management Software's language is English.

Comparison to Predicate Device

# r

<table><tr><td rowspan=1 colspan=3>Comparison</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>CERA-CHEK 1070</td><td rowspan=1 colspan=1>Ascensia® CONTOUR</td></tr><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Detection Method</td><td rowspan=1 colspan=1>Amperometry</td><td rowspan=1 colspan=1>Amperometry</td></tr><tr><td rowspan=1 colspan=1>Enzyme</td><td rowspan=1 colspan=1>Glucose dehydrogenase(FAD-GDH)</td><td rowspan=1 colspan=1>Glucose dehydrogenase(FAD-GDH)</td></tr><tr><td rowspan=1 colspan=1>Test Time</td><td rowspan=1 colspan=1>5 seconds</td><td rowspan=1 colspan=1>5 seconds</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Coding</td><td rowspan=1 colspan=1>No coding</td><td rowspan=1 colspan=1>No coding</td></tr><tr><td rowspan=1 colspan=1>Memory</td><td rowspan=1 colspan=1>1000 blood glucose test resultswith date and time</td><td rowspan=1 colspan=1>480 blood glucose test resultswith date and time</td></tr><tr><td rowspan=1 colspan=1>Test range</td><td rowspan=1 colspan=1>20-600 mg/dL</td><td rowspan=1 colspan=1>10-600 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>0.5 uL</td><td rowspan=1 colspan=1>0.6 uL</td></tr><tr><td rowspan=1 colspan=1>Humidity range</td><td rowspan=1 colspan=1>10-85%</td><td rowspan=1 colspan=1>10-93%</td></tr><tr><td rowspan=1 colspan=1>Temperature range</td><td rowspan=1 colspan=1>50-104°F10-40°C</td><td rowspan=1 colspan=1>41~113°F5-45°C</td></tr><tr><td rowspan=1 colspan=1>Power(Battery)</td><td rowspan=1 colspan=1>One 3-volt lithium battery(CR2032)</td><td rowspan=1 colspan=1>Two 3-volt lithium batteries(DL2032 or CR2032)</td></tr><tr><td rowspan=1 colspan=1>Level of QC</td><td rowspan=1 colspan=1>2 Levels (Control 1, Control 2)</td><td rowspan=1 colspan=1>3 Levels (Low. Normal, High)</td></tr><tr><td rowspan=1 colspan=1>Dimensions</td><td rowspan=1 colspan=1>94mm(H) x 53.6(W) x 14.9mm(T)</td><td rowspan=1 colspan=1>77mm(H) x 57mm(W) x 19mm(T)</td></tr><tr><td rowspan=1 colspan=1>Weight</td><td rowspan=1 colspan=1>40g</td><td rowspan=1 colspan=1>47.5g</td></tr><tr><td rowspan=1 colspan=1>Hematocrit range</td><td rowspan=1 colspan=1>10-70%</td><td rowspan=1 colspan=1>20-60%</td></tr></table>

# Conclusion

As the comparison table, the CERA-CHEK 1070 Blood Glucose Monitoring System have same detection method, test range, and test time. Furthermore, the CERA-CHEK 1070 Blood Glucose Monitoring System is also using same enzyme and mediator. To sum up with the similarities, the CERA-CHEK 1070 Blood Glucose Monitoring System is similar with the predicate device because most of the specifications deciding the characteristic of the device are same. In conclusion, despite of the difference such as memory, coding, and etc, the CERA-CHEK 1070 Blood Glucose Monitoring System is substantially equivalent as compared to the predicate device.

# 8. Performance Characteristics

1. Analytical performance

A. Precision/Reproducibility (1) Within-run Precision

Within-un precision was evaluated by analyzingvenous whole blood samples spiked to ive different glucose concentrations. The hematocrit of all samples was between 35 and 50%. Five different lot numbers of test srips and ten metrs were usd in the studyand each of the samples was measured ten times per srip lot number per meter for a total of 100 measurements per glucose concentration. The samples were analyzed by one operator in one day.

<table><tr><td rowspan=1 colspan=1>Interval</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Glucose concentration</td><td rowspan=1 colspan=1>30~50</td><td rowspan=1 colspan=1>51~110</td><td rowspan=1 colspan=1>111~150</td><td rowspan=1 colspan=1>151~250</td><td rowspan=1 colspan=1>251~400</td></tr><tr><td rowspan=1 colspan=1>YSI (mg/dL)</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>127</td><td rowspan=1 colspan=1>226</td><td rowspan=1 colspan=1>323</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>45.2</td><td rowspan=1 colspan=1>97.6</td><td rowspan=1 colspan=1>129.1</td><td rowspan=1 colspan=1>228.3</td><td rowspan=1 colspan=1>326.1</td></tr><tr><td rowspan=1 colspan=1>STD(mg/dL)</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>7.3</td></tr><tr><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>2.2</td></tr></table>

Day to day precision

Day t day precision was evaluate by nalyzicntrolsamplesat thre diffet coneratons. Threot numbers of test strips (one per glucose level) and ten meters were used in the study. Each of the control. levels was measured once per day over twenty. Each of the control levels was measured once per strip lot number per meter. In total, 600 measurements were taken for each of the three levels. Results are summarized below:

<table><tr><td rowspan=1 colspan=1>Interval</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Glucose concentration</td><td rowspan=1 colspan=1>30~50</td><td rowspan=1 colspan=1>96~144</td><td rowspan=1 colspan=1>280~420</td></tr><tr><td rowspan=1 colspan=1>YSI, mg/dL</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>304</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>42.6</td><td rowspan=1 colspan=1>108.4</td><td rowspan=1 colspan=1>303.8</td></tr><tr><td rowspan=1 colspan=1>STD(mg/dL)</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>8.6</td></tr><tr><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>2.8</td></tr></table>

# B.Linearity/assay reportable range

The soorevaluated t lncariy themeter by preparing a srs  glu mplsollow the diutin heme in CLSI EP6-A, and producing target values f 11,5, 89, 157, 234, 310, 386, 41, 51, a $6 0 7 ~ \mathrm { m g / d L }$ .

the YSl 2300 analyzer. Linear regression of the data produced the following:

<table><tr><td rowspan=1 colspan=1>Strip Lot</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Corr Coeff (r²)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.9896</td><td rowspan=1 colspan=1>1.4433</td><td rowspan=1 colspan=1>0.9995</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.9786</td><td rowspan=1 colspan=1>2.4223</td><td rowspan=1 colspan=1>0.9997</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.9782</td><td rowspan=1 colspan=1>4.4741</td><td rowspan=1 colspan=1>0.9992</td></tr></table>

The ul he por e 'caiemet $2 0 - 6 0 0 ~ \mathrm { m g / d L }$ .

C.Traceability, Stability, Expected values (controls, calibrators, or methods)

The CERA-CHEK 1070 Blood Glucose Monitoring System is traccable to the YSI 2300 Glucose analyzer which is calibrated using the YSI 2747 Glucose Standard which is a NIST traceable glucose standard.

Te heabil os wa sa u wi al t u The protocols and acceptance criteria were reviewed and found to be acceptable. The testing supported the claimed shelf life of 24 months when stored at $1 \cdot 3 2 ^ { \circ } \mathrm { C }$ and $10 \%$ RH.

Tes sri -use abiliy open vial) was assese n eal tme studie. The procols nd acptanc a wre reviewed and found to be acceptable. The testing supported the open vial stability of four months when stored at $1 - 3 2 ^ { \circ } \mathrm { C }$ and $10 \mathrm { - } 8 5 \%$ RH.

Control shelf-e stabilityclosed vial) was assessed anacclerate study with real time studis ongoin. The protocols and acceptance criteria were reviewed and found to be acceptable. The testing supported the claimed shelf life of 12 months when stored at ${ \| - 3 2 ^ { \circ } \ C }$ and below $5 0 \%$ RH.

Control in-use stability (open vial) was assessed in real-time studies. The protocols and acceptance cteia v

stored at $1 - 3 2 ^ { \circ } \mathrm { C }$ and below $5 0 \%$ RH.

Detection Limit

The meign  s $2 0 - 6 0 0 \mathrm { m g / d l } _ { - }$ T n   hey

E. Analytical specificity

The sponsor performed interference studies in accordance with CLSI EP7-A. Testing was performed in parallel (control samples vs. test samples) to minimize the effects of glucose metabolism. Whole blood was drawn into K3-EDTA anticoagulant tubes from healthy volunteers who were not on any medications. The glucose levels tested were 64, 151, and 257 mg/dL. The highest level was achieved by spiking. A low and high concentration of each potential intererent was then tested at each glucose level. The following substances were found not to interfere at the concentrations listed:

<table><tr><td colspan="1" rowspan="1">Substance</td><td colspan="1" rowspan="1">No interference up to:</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">6 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Ascorbic acid</td><td colspan="1" rowspan="1">4 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Dopamine</td><td colspan="1" rowspan="1">5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">40 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Metformin</td><td colspan="1" rowspan="1">4 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Methyldopa</td><td colspan="1" rowspan="1">5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Salicylic acid</td><td colspan="1" rowspan="1">50 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Uric acid</td><td colspan="1" rowspan="1">10 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Bilirubin</td><td colspan="1" rowspan="1">4 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Triglyceride</td><td colspan="1" rowspan="1">1,500 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Cholesterol</td><td colspan="1" rowspan="1">500 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">10 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Galactose</td><td colspan="1" rowspan="1">100 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Gentisic acid</td><td colspan="1" rowspan="1">2 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Glutathione</td><td colspan="1" rowspan="1">3 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">20 g/dL</td></tr><tr><td colspan="1" rowspan="1">L-dopa</td><td colspan="1" rowspan="1">4 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Maltose</td><td colspan="1" rowspan="1">100 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Sodium</td><td colspan="1" rowspan="1">150 mmol/L</td></tr><tr><td colspan="1" rowspan="1">Tolbutamide</td><td colspan="1" rowspan="1">64 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Tolazamide</td><td colspan="1" rowspan="1">5 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Xylose</td><td colspan="1" rowspan="1">10 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Mannitol</td><td colspan="1" rowspan="1">800 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Sorbitol</td><td colspan="1" rowspan="1">100 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Xylitol</td><td colspan="1" rowspan="1">100 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Lactitol</td><td colspan="1" rowspan="1">100 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Isomalt</td><td colspan="1" rowspan="1">100 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Maltitol</td><td colspan="1" rowspan="1">100 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Hydrogenated starchhydrolysates</td><td colspan="1" rowspan="1">100 mg/dL</td></tr></table>

The sponsor has the following limitations in their labeling:

• High concentrations of dopamine, methyldopa, and Tolazamide may cause inaccurate test results Do not use during or soon after xylose absorption testing. Xylose $\scriptstyle ( > 1 0 \mathrm { m g } / \mathrm { d L } )$ in the blood will cause interference.

# 2. Comparison studies

A.Method comparison with predicate device

For the user perormance sudy, 200 participants collectand tested twice thcir own figrstic sample nigl measurements on the CERA-CHEK 1070 BGMS. The healthcare professional tested the collected samples of 200 participants and 20 contrived samples on CERA-CHEK 1070 BGMS. Within five minutes, fingerstick smple was collect rom eac participant by a healthcare proesional or the syste accuracy sudy and was tested on the YSI 2300 reference analyzer.

# System Accuracy Study

Difference distribution for glucose concentration $< 7 5 m g / \mathrm { d L }$

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>Technician</td><td rowspan=1 colspan=1>User</td></tr><tr><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>within ±5mg/dL</td><td rowspan=1 colspan=1>77%(36/47)</td><td rowspan=1 colspan=1>55%(21/38)</td></tr><tr><td rowspan=1 colspan=1>within ±10mg/dL</td><td rowspan=1 colspan=1>89%(42/47)</td><td rowspan=1 colspan=1>87%(33/38)</td></tr><tr><td rowspan=1 colspan=1>within ±15mg/dL</td><td rowspan=1 colspan=1>100%(47/47)</td><td rowspan=1 colspan=1>100%(38/38)</td></tr></table>

Note: One contrived sample was $< 2 0$ mg/dL and therefore not included in data analysis.

Difference(%) distribution for glucose concentration $\geq 7 5 m g / \mathrm { d L }$   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>Technician</td><td rowspan=1 colspan=1>User</td></tr><tr><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>within ±5%</td><td rowspan=1 colspan=1>58%(100/171)</td><td rowspan=1 colspan=1>56%(91/162)</td></tr><tr><td rowspan=1 colspan=1>within ±10%</td><td rowspan=1 colspan=1>82%(140/171)</td><td rowspan=1 colspan=1>76%(123/162)</td></tr><tr><td rowspan=1 colspan=1>within ±15%</td><td rowspan=1 colspan=1>96%(164/171)</td><td rowspan=1 colspan=1>94%(152/162)</td></tr><tr><td rowspan=1 colspan=1>within ±20%</td><td rowspan=1 colspan=1>100%(171/171)</td><td rowspan=1 colspan=1>100%(162/162)</td></tr></table>

Note: One contrived sample was ${ \mathrm { > } } 6 0 0 { \mathrm { ~ m g / d L } }$ and therefore not included in data analysis.

# Linear regression

<table><tr><td></td><td>Slope</td><td>Intercept (95% Confidence Interval)</td><td>Correlation coefficient</td></tr><tr><td>Technician vs YSI</td><td>1.0365 (1.0223~1.0507)</td><td>-5.5769 (-8.2708~-2.8831)</td><td>0.9948</td></tr><tr><td>User vs YSI</td><td>1.0322 (1.0117~1.0527)</td><td>-3.0441 (-6.4963~0.1081)</td><td>0.9901</td></tr></table>

# BAlternate Site Test

The study was performed with a total 100 volunteer's samples. Samples of alterative site were measured by volunteer and professional on the meter and were measured on reference analyzer.

Difference distribution for glucose concentration $< 7 5 m g / \mathrm { d L }$

- Professional   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Palm capillary blood</td><td rowspan=1 colspan=1>Forearm capillary blood</td><td rowspan=1 colspan=1>Upper arm capillary blood</td><td rowspan=1 colspan=1>Thigh capillary blood</td><td rowspan=1 colspan=1>Calf capillary blood</td></tr><tr><td rowspan=1 colspan=1>withint5mg/dL.</td><td rowspan=1 colspan=1>80%(4/5)</td><td rowspan=1 colspan=1>60%(3/5)</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>80%(4/5)</td><td rowspan=1 colspan=1>80%(4/5)</td></tr><tr><td rowspan=1 colspan=1>within±10mg/dL</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>80%(4/5)</td><td rowspan=1 colspan=1>100%(5/5)</td></tr><tr><td rowspan=1 colspan=1>within±15mg/dL</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td></tr></table>

- lay user   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Palm capillaryblood</td><td rowspan=1 colspan=1>Forcarm capillaryblood</td><td rowspan=1 colspan=1>Upper arm capillaryblood</td><td rowspan=1 colspan=1>Thigh capillaryblood</td><td rowspan=1 colspan=1>Calf capillaryblood</td></tr><tr><td rowspan=1 colspan=1>within±Smg/dL.</td><td rowspan=1 colspan=1>80%(4/5)</td><td rowspan=1 colspan=1>80%(4/5)</td><td rowspan=1 colspan=1>80%4/5)</td><td rowspan=1 colspan=1>80%(4/5)</td><td rowspan=1 colspan=1>80%(4/5)</td></tr><tr><td rowspan=1 colspan=1>withint 10mg/dL</td><td rowspan=1 colspan=1>100%5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td></tr><tr><td rowspan=1 colspan=1>within±15mg/dL</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td><td rowspan=1 colspan=1>100%(5/5)</td></tr></table>

Difference distribution for glucose concentration $\geq 7 5 \mathrm { m g / d L }$ - Professional

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Palm capillaryblood</td><td rowspan=1 colspan=1>Forearm capillaryblood</td><td rowspan=1 colspan=1>Upper arm capillaryblood</td><td rowspan=1 colspan=1>Thigh capillaryblood</td><td rowspan=1 colspan=1>Calf capillaryblood</td></tr><tr><td rowspan=1 colspan=1>withint5%</td><td rowspan=1 colspan=1>73%(70/95)</td><td rowspan=1 colspan=1>59% 56/95)</td><td rowspan=1 colspan=1>65%(62/95)</td><td rowspan=1 colspan=1>66%(63/95)</td><td rowspan=1 colspan=1>64%61/95)</td></tr><tr><td rowspan=1 colspan=1>within±10%</td><td rowspan=1 colspan=1>78%(74/95)</td><td rowspan=1 colspan=1>71%(67/95)</td><td rowspan=1 colspan=1>77%(73/95)</td><td rowspan=1 colspan=1>77%(73/95)</td><td rowspan=1 colspan=1>71%(67/95)</td></tr><tr><td rowspan=1 colspan=1>within±15%</td><td rowspan=1 colspan=1>93%(88/95)</td><td rowspan=1 colspan=1>95%(90/95)</td><td rowspan=1 colspan=1>95%(90/95)</td><td rowspan=1 colspan=1>97%(92/95)</td><td rowspan=1 colspan=1>98%(93/95)</td></tr><tr><td rowspan=1 colspan=1>within±20%</td><td rowspan=1 colspan=1>100%(95/95)</td><td rowspan=1 colspan=1>100%(95/95)</td><td rowspan=1 colspan=1>100%(95/95)</td><td rowspan=1 colspan=1>100%(95/95)</td><td rowspan=1 colspan=1>100%(95/95)</td></tr></table>

- Lay user   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Palm capillaryblood</td><td colspan="1" rowspan="1">Forcamm capillaryblood</td><td colspan="1" rowspan="1">Upper arm capillaryblood</td><td colspan="1" rowspan="1">Thigh capillaryblood</td><td colspan="1" rowspan="1">Calf capillaryblood</td></tr><tr><td colspan="1" rowspan="1">within±5%</td><td colspan="1" rowspan="1">62%(59/95)</td><td colspan="1" rowspan="1">62%(59/95)</td><td colspan="1" rowspan="1">64%(61/95)</td><td colspan="1" rowspan="1">65%(62/95)</td><td colspan="1" rowspan="1">57%(54/95)</td></tr><tr><td colspan="1" rowspan="1">within±10%</td><td colspan="1" rowspan="1">66%(63/95)</td><td colspan="1" rowspan="1">73%(69/95)</td><td colspan="1" rowspan="1">72%(68/95)</td><td colspan="1" rowspan="1">72%(68/95)</td><td colspan="1" rowspan="1">75%(71/95)</td></tr><tr><td colspan="1" rowspan="1">within±15%</td><td colspan="1" rowspan="1">94%(89/95)</td><td colspan="1" rowspan="1">93%(88/95)</td><td colspan="1" rowspan="1">96%(91/95)</td><td colspan="1" rowspan="1">94%(89/95)</td><td colspan="1" rowspan="1">97%(92/95)</td></tr><tr><td colspan="1" rowspan="1">within±20%</td><td colspan="1" rowspan="1">100%(95/95)</td><td colspan="1" rowspan="1">100%(95/95)</td><td colspan="1" rowspan="1">100%(95/95)</td><td colspan="1" rowspan="1">100%(95/95)</td><td colspan="1" rowspan="1">100%(95/95)</td></tr></table>

Linear regression and correlation coefficient.

- Professional

<table><tr><td rowspan=2 colspan=1>••</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Correlation coefficient</td></tr><tr><td rowspan=1 colspan=3>(95% confidence interval)</td></tr><tr><td rowspan=2 colspan=1>Palm capillary vs YSI</td><td rowspan=1 colspan=1>1.0230</td><td rowspan=1 colspan=1>2.1615</td><td rowspan=2 colspan=1>0.9963</td></tr><tr><td rowspan=1 colspan=1>(1.0054~1.0406)</td><td rowspan=1 colspan=1>(-1.4008~5.7239)</td></tr><tr><td rowspan=2 colspan=1>Forearm capillary vs YSI</td><td rowspan=1 colspan=1>1.0519</td><td rowspan=1 colspan=1>-0.0445</td><td rowspan=2 colspan=1>0.9967</td></tr><tr><td rowspan=1 colspan=1>(1.0347~1.0692)</td><td rowspan=1 colspan=1>(-3.5308~3.4419)</td></tr><tr><td rowspan=2 colspan=1>Upper arm capillary vs YSI</td><td rowspan=1 colspan=1>1.0396</td><td rowspan=1 colspan=1>0.0729</td><td rowspan=2 colspan=1>0.9957</td></tr><tr><td rowspan=1 colspan=1>(1.0202~1.0590)</td><td rowspan=1 colspan=1>(-3.8584~4.0043)</td></tr><tr><td rowspan=2 colspan=1>Thigh capillary vs YSI</td><td rowspan=1 colspan=1>1.0303</td><td rowspan=1 colspan=1>0.5266</td><td rowspan=2 colspan=1>0.9957</td></tr><tr><td rowspan=1 colspan=1>(1.0109~1.0496)</td><td rowspan=1 colspan=1>(-3.3818~4.4350)</td></tr><tr><td rowspan=2 colspan=1>Calf capillary vs YSI</td><td rowspan=1 colspan=1>1.0364</td><td rowspan=1 colspan=1>0.7075</td><td rowspan=2 colspan=1>0.9945</td></tr><tr><td rowspan=1 colspan=1>(1.0144~1.0583)</td><td rowspan=1 colspan=1>(-3.7344~5.1494)</td></tr></table>

- Lay user   

<table><tr><td rowspan=2 colspan=1>••</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Correlation coefficient</td></tr><tr><td rowspan=1 colspan=3>(95% confidence interval)</td></tr><tr><td rowspan=2 colspan=1>Palm capillary vs YSI</td><td rowspan=1 colspan=1>1.0504</td><td rowspan=1 colspan=1>-1.5331</td><td rowspan=2 colspan=1>0.9955</td></tr><tr><td rowspan=1 colspan=1>(1.0305~1.0704)</td><td rowspan=1 colspan=1>(-5.5767~2.5105)</td></tr><tr><td rowspan=2 colspan=1>Forearm capillary vs YSI</td><td rowspan=1 colspan=1>1.0317</td><td rowspan=1 colspan=1>2.1956</td><td rowspan=2 colspan=1>0.9965</td></tr><tr><td rowspan=1 colspan=1>(1.0143~1.0491)</td><td rowspan=1 colspan=1>(-1.3207~5.7120)</td></tr><tr><td rowspan=2 colspan=1>Upper arm capillary vs YSI</td><td rowspan=1 colspan=1>1.0254</td><td rowspan=1 colspan=1>1.9080</td><td rowspan=2 colspan=1>0.9956</td></tr><tr><td rowspan=1 colspan=1>(1.0059~1.0448)</td><td rowspan=1 colspan=1>(-2.0296~5.8455)</td></tr><tr><td rowspan=2 colspan=1>Thigh capillary vs YSI</td><td rowspan=1 colspan=1>1.0405</td><td rowspan=1 colspan=1>-0.9615</td><td rowspan=2 colspan=1>0.9933</td></tr><tr><td rowspan=1 colspan=1>(1.0163~1.0648)</td><td rowspan=1 colspan=1>(-5.8634~3.9404)</td></tr><tr><td rowspan=2 colspan=1>Calf capillary vs YSI</td><td rowspan=1 colspan=1>1.0352</td><td rowspan=1 colspan=1>1.7561</td><td rowspan=2 colspan=1>0.9962</td></tr><tr><td rowspan=1 colspan=1>(1.0170~1.0535)</td><td rowspan=1 colspan=1>(-1.9340~5.4461)</td></tr></table>

# 3. Other Supportive Instrument Performance Characteristics Data Not Covered In the Performance Characteristics" Section above

A. Hematocrit study The effect of different hematocrit levels was evaluated using venous whole blood samples with hematocrit levels across the claimed range and altered to glucose concentrations from $2 1 - 5 2 9 \mathrm { m g / d L }$ There were five measurements for each combination of glucose concentration and hematocrit level. The results demonstrated that CERA-CHEK 1070 Blood Glucose Monitoring System produces accurate results over the claimed hematocrit range of $10 - 7 0 \%$

# B Altitude study

A y was conduced to evaluate the efct oltitueon te devic In this evaluainvnou blooa glucose concentrations of approximately 100. 200, and $3 0 0 \mathrm { m g / d L }$ was tested using a decompression chamber to sulate theefects oaltitude.Three lots of test strips and three meters were used. Each blood sample was also tested by the YSI 2300 analyzer. The meter readings obtained were compared to the YSl method and the percent bias was determined at each level against the YSl results. The results demonstrated that the CERA-CHEK 1070 Blood Glucose Monitoring System produces accurate results at altitudes up to 13,200 feet.

# C. Temperature and humidity studies

In this study, three test srip lots were tested on three meters at three glucose concentrations (approximately 45, 120, and $3 0 0 ~ \mathrm { m g / d L }$ ) at twelve combinations of temperature and humidity. Each combination of environmental conditions / glucose concentration / meter was tested in replicates of three. The temperatures tested ranged from a low of $1 0 . 0 ^ { \circ } \mathrm { C }$ to a high of $4 1 . 2 ^ { \circ } \mathrm { C }$ The relative humidity tested ranged from $1 0 . 3 \%$ - 86.6%. Glucose concentrations were verified by the YSl reference method. The bias relative to the reference mcthod was acceptable to support the claim that temperatures from $1 0 - 4 0 ^ { \circ } \mathrm { ~ C ~ } ( 5 0 - 1 0 4 ^ { \circ } \mathrm { ~ F ~ } )$ and relative humidity from $1 0 - 8 5 \%$ do not significantly affect the glucose results.

# DInfection Control Studies

The CERAGEM MEDISYS CERA-CHEK 1070 Blood Glucose Monitoring System is intended for singlepatient use only. Disinfection efficacy studies were performed on the materials comprising the meter and lancing device by an outside commercial testing facility demonstrating complete inactivation of hepatitis B virus (HBV) with the chosen disinfectant, CaviWipes (EPA Registration Number 46781-8). Robustness

studies were also performed by the sponsor demonstrating that there was no change in performance or external materials for the mcter and lancing device after 1825 cleanings and 1825 disinfection steps with CaviWipes. The robustness studies were designed to simulate  years of single-patient use. Labeling was reviewed for adequate instructions for the validated cleaning and disinfection procedures.

# E. Usability Study

A usability study was performed to assess the readability of the labeling by recruiting untrained lay users who were provided with the test kit and labeling. These lay users also completed a questionnaire regarding t  e they understood the instructions and were able to successfully operate the device.

CERAGEM MEDISYS, INC.   
HAKSUNG KIM   
3-2, JEONGCHON-RI, SEONGGEO-EUP, SEOBUK-GU, CHEONAN-SI, CHUNGCHEONGNAM-D0 331-833   
REPUBLIC OF KOREA

Re: K131727 Trade/Device Name: CERA-CHEK 1070 Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: II Product Code: LFR, NBW, JJX, JQP Dated: January 06, 2014 Received: January 10, 2014

Dear Haksung Kim:

We have reviewed your Section ${ \mathfrak { s l o } } ( { \mathbf k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (or the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, ad CosmeicAct (Act) that do not requie approval o a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The al contros provisions he Act icuerequirments ranual egstratin, st devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.Please note:CDRH does not evaluate information related to contract liability warrWemyhowr h vbut tund otis yo evc c ebovetithlassScl cass  A, it may be subject to additional controls. Existing major regulations affecting your device can be fd inhe CodeFederal Regulations, T , ar 0 to In dition, y publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

Page 2—Haksung Kim

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809). please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Intemet address http://wwv.fda.gov/MedicalDeviccs/RcsourcesforYou/lndustry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 87.9. For questions regarding the reporting of adverse events under the MDR regulation 21 CFR Part 803). please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office ofSurveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Courtney H. Lias -S

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

# Indications for Use

# 510(k) Number (if known): k131727

# Device Name: CERA-CHEK 1070 Blood Glucose Monitoring System

Indications for Use:

The CERA-CHEK 1070 Blood Glucose Monitoring System is intended to be used for the quantitative tuc  pio p forearm, upper arm, palm, thigh, or calf. The CERA-CHEK 1070 Blood Glucose Monitoring System is intended to be used by a single person and should not be shared. Alternative site testing should be done only during steady-state times (when glucose is not changing rapidly).

The CERA-CHEK 1070 Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes controls. The CERA-CHEK 1070 Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use.

The CERA-CHEK 1070 Blood Glucose Test Strips are for use with the CERA-CHEK 1070 Blood GuTt Meniativeyeasuegucoe ugar apillyholbloope drawn from the fingertip, forearm, upper arm, palm, thigh, or calf.

The CERA-CHEK 1070 Control Solution is for use with the CERA-CHEK 1070 Blood Glucose Test Meter and Test strips as a quality control check to verify that the meter and test strips are working together properly and that the test is performing correctly.

The CERA-CHEK Diabetes Management Software is PC-based software intended for use in home and i accessory to compatible CERAGEM MEDISYS blood glucose monitoring systems. The CERA-CHEK Diabetes Management Software's language is English.

And/Or

Prescription Use (21 CFR Part 801 Subpart D)

Over the Counter Use V. (21 CFR Part 801 Subpart C)